Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| treatment with radium-223 Dichloride (Xofigo) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radium-223 dichloride | Drug | Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in number of osteoblastic bone lesions | number of lesions specified before and after the treatment with a bone scan | Pretreatment (about 30 days before treatment) and post treatment (about 4 weeks after treatment) |
| Measure | Description | Time Frame |
|---|---|---|
| functional status as indicated by score on the Eastern Cooperative Oncology Group (ECOG) performance scale | The ECOG scale describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The possible scores on the scale are 0 to 5, with 0 being the best outcome and 5 being the worst outcome, details of each score are listed below. Grade 0 = Fully active, able to carry on all pre-disease performance without restriction Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work Grade 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours Grade 3 = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours Grade 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair Grade 5 = Dead |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Males presenting with prostate cancer.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Isis W Gayed, MD | The University of Texas Health Science Center, Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C581106 | radium Ra 223 dichloride |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Pretreatment (about 1 to 3 days before each treatment) for a total of 6 treatments |
| pain level as assessed by numeric rating score | As assessed using numeric rating score from 1-10 with 10 being the highest level of pain | Pretreatment (about 1 to 3 days before each treatment) for a total of 6 treatments |
| (PSA) prostate specific antigen level | normal level should be 4.0 ng/mL. value is measured after each dose | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |
| (ALP) alkaline phosphatase level | The normal value for alkaline phosphatase is 53 to 128 U/L. | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |
| Hemoglobin level | The normal level for males is 14 to 18 g/dl | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |
| Platelet level | A normal platelet count ranges from 150,000 to 450,000 platelets | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |
| Neutrophil count | The normal range for neutrophils is 2.5-7.5 x 10 9 /L | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |
| Creatinine level | Normal levels of creatinine in the blood are approximately 0.6 to 1.2 milligrams (mg) per deciliter (dL) | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |
| white blood cell count | The typical white blood cell count varies from 4,000 to 10,000 cells per mm3. | pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments |